Eledon Achieves Significant Milestones in Kidney Transplant Program
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 13 2026
0mins
Should l Buy ELDN?
"In the first quarter of 2026, we achieved significant milestones in our tegoprubart program, including important data updates in kidney and islet cell transplantation and FDA Orphan Drug designation for tegoprubart in liver transplantation," said David-Alexandre C. Gros, Chief Executive Officer of Eledon. "Looking ahead, we expect multiple catalysts in 2026, including regulatory engagements supporting the advancement of tegoprubart into Phase 3 development in kidney transplantation and discussions regarding a potential path to market in islet cell transplantation. We also plan to initiate several new clinical trials, including an investigator sponsored study in liver transplantation, and share new kidney transplant data from our Phase 2 BESTOW long-term extension study, building on encouraging 24-month Phase 1b results that demonstrated a durable safety profile and improved graft function."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ELDN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ELDN
Wall Street analysts forecast ELDN stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.580
Low
4.00
Averages
7.75
High
10.00
Current: 3.580
Low
4.00
Averages
7.75
High
10.00
About ELDN
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. Tegoprubart is engineered to potentially both improve safety and provides pharmacokinetic, pharmacodynamic, and dosing advantages. CD40L is primarily expressed on activated CD4+ T cells, platelets, and endothelial cells while the CD40 receptor is constitutively expressed on antigen-presenting cells, such as macrophages and dendritic cells, as well as B cells.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eledon Pharmaceuticals Q1 Earnings Miss Expectations
- Earnings Report Shortfall: Eledon Pharmaceuticals reported a Q1 GAAP EPS of -$0.33, missing expectations by $0.12, indicating ongoing challenges in profitability that could undermine investor confidence.
- Cash Flow Status: As of March 31, 2026, the company had $111.1 million in cash, cash equivalents, and short-term investments, down from $133.3 million as of December 31, 2025, reflecting tightening liquidity that may limit future operational flexibility.
- Funding Outlook: Eledon expects its current cash and short-term investments to fund operations into Q2 2027, providing short-term financial security but also indicating reliance on future financing.
- Market Reaction: Despite the earnings miss, Eledon Pharmaceuticals' stock rose due to its lead asset Tegoprubart receiving FDA orphan drug status, demonstrating market recognition of its product potential and possibly providing momentum for future growth.
See More
NewcelX Collaborates with Eledon to Advance Diabetes Treatment
- Strategic Collaboration Highlight: NewcelX's partnership with Eledon Pharmaceuticals integrates its stem-cell-derived islet replacement platform with Eledon's immune modulation therapy, aiming to enhance treatment success rates and provide patients with more durable graft survival.
- Core Program Advancement: NCEL-101, NewcelX's flagship program, focuses on restoring insulin production through scalable cell replacement therapy, marking a strategic emphasis in diabetes treatment that is expected to significantly improve patient quality of life.
- Industry Presentation Plans: NewcelX plans to showcase its updated corporate presentation at the upcoming Swiss Biotech Conference, emphasizing its development vision for the diabetes program to attract more investment and collaboration opportunities.
- Forward-Looking Statements: The company notes in its press release that while the collaboration appears promising, it faces multiple uncertainties related to technology, market conditions, and regulatory approvals that could impact the progress of clinical trials and market acceptance of its products.
See More
Cell Therapy Market Set to Nearly Double by 2035
- Market Growth Potential: The global cell therapy manufacturing market is projected to grow from $7.17 billion in 2026 to over $14 billion by 2035, with a compound annual growth rate of 15.2%, indicating strong demand and investment appeal in this sector.
- FDA Policy Advancement: In early 2026, the FDA formalized flexible manufacturing and quality control oversight, clearing the path for the transition from clinical validation to commercial products, thus accelerating industry growth and innovation.
- Avaí Bio's Progress: Avaí Bio, in partnership with Austrianova, has commenced the production of a Master Cell Bank (MCB) for α-Klotho protein, establishing a foundational infrastructure that ensures compliance with the highest quality standards for future cell therapy products.
- Technological Innovation and Market Demand: Avaí Bio's Cell-in-a-Box® encapsulation platform will utilize cells from the MCB to create a therapy that continuously produces Klotho protein, addressing the growing demand for anti-aging treatments and holding significant market potential.
See More
Eledon Pharmaceuticals Reports Expanded Net Loss for FY 2025 and Operational Updates
- Financial Overview: Eledon Pharmaceuticals reported an expanded net loss of $45.6 million for FY 2025, translating to a loss of $0.52 per share, compared to $36.2 million and $0.66 per share in the previous year, indicating ongoing pressures in R&D and operations that may affect future funding capabilities.
- Drug Development Progress: The lead candidate Tegoprubart received Orphan Drug designation from the FDA for liver transplantation, and 24-month follow-up data from eight patients was presented at the American Society of Transplant Surgeons Winter Symposium, further supporting its safety and tolerability profile with no reported adverse events, enhancing market confidence.
- Diabetes Patient Trial Results: In a study involving 12 patients with type 1 diabetes, 10 patients achieved 100% insulin independence after more than four weeks, with the latest hemoglobin A1c (HbA1c) levels below 6.0% and an average HbA1c of approximately 5.35%, demonstrating Tegoprubart's potential in immunosuppressive therapy and generating inquiries from several hundred patients.
- Expected Future Milestones: The company anticipates receiving FDA guidance on the Phase 3 trial design for Tegoprubart in kidney transplantation, with plans to initiate the trial pending regulatory alignment, and will report long-term data from Phase 1 and Phase 2 BESTOW studies, reflecting a proactive approach to advancing product commercialization.
See More
Eledon Pharmaceuticals Reports FY 2025 Earnings Beat Expectations
- Earnings Highlights: Eledon Pharmaceuticals reported a FY 2025 GAAP EPS of -$0.52, beating expectations by $0.15, indicating a positive trend in improving profitability despite still being in a loss position.
- Cash Position: As of FY 2025, Eledon's cash, cash equivalents, and short-term investments totaled $133.33 million, down from $140.18 million in FY 2024, reflecting challenges in financial management and operational expenditures.
- Product Development: Eledon's lead asset, Tegoprubart, received FDA orphan drug status, highlighting its potential in the immunosuppressive market and possibly providing new revenue growth opportunities for the company.
- Market Reaction: Eledon Pharmaceuticals' stock rose due to the earnings beat and FDA approval news, indicating increased investor confidence in the company's future, which may attract more attention from investors regarding its long-term growth potential.
See More
Eledon Pharmaceuticals Reports Positive Data on Tegopribart for Type 1 Diabetes
- Clinical Trial Results: In a cohort of 12 patients undergoing allogeneic islet transplantation for type 1 diabetes, 10 achieved 100% insulin independence four weeks post-transplant, demonstrating significant efficacy that could reshape diabetes treatment paradigms.
- Immunosuppressive Advantage: Tegopribart, an anti-CD40L monoclonal antibody, showed no signs of graft rejection or de novo donor-specific human leukocyte antigen antibodies, indicating its potential as a safer treatment option for patients requiring immunosuppression.
- Market Outlook: With the FDA granting orphan drug status to Eledon Pharmaceuticals' lead asset, the company significantly enhances its market opportunities in diabetes treatment, likely attracting increased investor interest.
- Financial Performance: Historical earnings data for Eledon Pharmaceuticals suggests that as drug development progresses, the company's future revenue potential will substantially increase, further solidifying its position in the biopharmaceutical industry.
See More
Eledon Pharmaceuticals Q1 Earnings Miss Expectations
- Earnings Report Shortfall: Eledon Pharmaceuticals reported a Q1 GAAP EPS of -$0.33, missing expectations by $0.12, indicating ongoing challenges in profitability that could undermine investor confidence.
- Cash Flow Status: As of March 31, 2026, the company had $111.1 million in cash, cash equivalents, and short-term investments, down from $133.3 million as of December 31, 2025, reflecting tightening liquidity that may limit future operational flexibility.
- Funding Outlook: Eledon expects its current cash and short-term investments to fund operations into Q2 2027, providing short-term financial security but also indicating reliance on future financing.
- Market Reaction: Despite the earnings miss, Eledon Pharmaceuticals' stock rose due to its lead asset Tegoprubart receiving FDA orphan drug status, demonstrating market recognition of its product potential and possibly providing momentum for future growth.
See More
NewcelX Collaborates with Eledon to Advance Diabetes Treatment
- Strategic Collaboration Highlight: NewcelX's partnership with Eledon Pharmaceuticals integrates its stem-cell-derived islet replacement platform with Eledon's immune modulation therapy, aiming to enhance treatment success rates and provide patients with more durable graft survival.
- Core Program Advancement: NCEL-101, NewcelX's flagship program, focuses on restoring insulin production through scalable cell replacement therapy, marking a strategic emphasis in diabetes treatment that is expected to significantly improve patient quality of life.
- Industry Presentation Plans: NewcelX plans to showcase its updated corporate presentation at the upcoming Swiss Biotech Conference, emphasizing its development vision for the diabetes program to attract more investment and collaboration opportunities.
- Forward-Looking Statements: The company notes in its press release that while the collaboration appears promising, it faces multiple uncertainties related to technology, market conditions, and regulatory approvals that could impact the progress of clinical trials and market acceptance of its products.
See More
Cell Therapy Market Set to Nearly Double by 2035
- Market Growth Potential: The global cell therapy manufacturing market is projected to grow from $7.17 billion in 2026 to over $14 billion by 2035, with a compound annual growth rate of 15.2%, indicating strong demand and investment appeal in this sector.
- FDA Policy Advancement: In early 2026, the FDA formalized flexible manufacturing and quality control oversight, clearing the path for the transition from clinical validation to commercial products, thus accelerating industry growth and innovation.
- Avaí Bio's Progress: Avaí Bio, in partnership with Austrianova, has commenced the production of a Master Cell Bank (MCB) for α-Klotho protein, establishing a foundational infrastructure that ensures compliance with the highest quality standards for future cell therapy products.
- Technological Innovation and Market Demand: Avaí Bio's Cell-in-a-Box® encapsulation platform will utilize cells from the MCB to create a therapy that continuously produces Klotho protein, addressing the growing demand for anti-aging treatments and holding significant market potential.
See More
Eledon Pharmaceuticals Reports Expanded Net Loss for FY 2025 and Operational Updates
- Financial Overview: Eledon Pharmaceuticals reported an expanded net loss of $45.6 million for FY 2025, translating to a loss of $0.52 per share, compared to $36.2 million and $0.66 per share in the previous year, indicating ongoing pressures in R&D and operations that may affect future funding capabilities.
- Drug Development Progress: The lead candidate Tegoprubart received Orphan Drug designation from the FDA for liver transplantation, and 24-month follow-up data from eight patients was presented at the American Society of Transplant Surgeons Winter Symposium, further supporting its safety and tolerability profile with no reported adverse events, enhancing market confidence.
- Diabetes Patient Trial Results: In a study involving 12 patients with type 1 diabetes, 10 patients achieved 100% insulin independence after more than four weeks, with the latest hemoglobin A1c (HbA1c) levels below 6.0% and an average HbA1c of approximately 5.35%, demonstrating Tegoprubart's potential in immunosuppressive therapy and generating inquiries from several hundred patients.
- Expected Future Milestones: The company anticipates receiving FDA guidance on the Phase 3 trial design for Tegoprubart in kidney transplantation, with plans to initiate the trial pending regulatory alignment, and will report long-term data from Phase 1 and Phase 2 BESTOW studies, reflecting a proactive approach to advancing product commercialization.
See More
Eledon Pharmaceuticals Reports FY 2025 Earnings Beat Expectations
- Earnings Highlights: Eledon Pharmaceuticals reported a FY 2025 GAAP EPS of -$0.52, beating expectations by $0.15, indicating a positive trend in improving profitability despite still being in a loss position.
- Cash Position: As of FY 2025, Eledon's cash, cash equivalents, and short-term investments totaled $133.33 million, down from $140.18 million in FY 2024, reflecting challenges in financial management and operational expenditures.
- Product Development: Eledon's lead asset, Tegoprubart, received FDA orphan drug status, highlighting its potential in the immunosuppressive market and possibly providing new revenue growth opportunities for the company.
- Market Reaction: Eledon Pharmaceuticals' stock rose due to the earnings beat and FDA approval news, indicating increased investor confidence in the company's future, which may attract more attention from investors regarding its long-term growth potential.
See More
Eledon Pharmaceuticals Reports Positive Data on Tegopribart for Type 1 Diabetes
- Clinical Trial Results: In a cohort of 12 patients undergoing allogeneic islet transplantation for type 1 diabetes, 10 achieved 100% insulin independence four weeks post-transplant, demonstrating significant efficacy that could reshape diabetes treatment paradigms.
- Immunosuppressive Advantage: Tegopribart, an anti-CD40L monoclonal antibody, showed no signs of graft rejection or de novo donor-specific human leukocyte antigen antibodies, indicating its potential as a safer treatment option for patients requiring immunosuppression.
- Market Outlook: With the FDA granting orphan drug status to Eledon Pharmaceuticals' lead asset, the company significantly enhances its market opportunities in diabetes treatment, likely attracting increased investor interest.
- Financial Performance: Historical earnings data for Eledon Pharmaceuticals suggests that as drug development progresses, the company's future revenue potential will substantially increase, further solidifying its position in the biopharmaceutical industry.
See More
